ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Esperion Therapeutics (ESPR) Misses Q4 EPS by 13c, Revenues Miss
February 23, 2021 4:43 PM ESTEsperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of ($3.89), $0.13 worse than the analyst estimate of ($3.76). Revenue for the quarter came in at $9.64 million versus the consensus estimate of $12.52 million.
Even though 2020 was an exceptionally challenging year, we made progress in our mission of Lipid... More
